A Randomized, Open-label, Parallel-controlled Phase 3 Study of Combination JMT101 and Osimertinib Compared With Cisplatin -Pemetrexed in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This clinical trial is focused on finding an effective treatment for patients with a specific type of advanced lung cancer, known as non-small cell lung cancer, which has a mutation called EGFR Exon 20 insertion. The study compares two treatment combinations: JMT101 with Osimertinib, and Cisplatin with Pemetrexed. This trial is important because patients with this mutation often have limited treatment options, and the study aims to discover if the new combination can provide better outcomes in terms of slowing down the progression of the disease. Participants in this trial will be randomly assigned to receive one of the two treatment combinations. One group will receive JMT101 and Osimertinib, while the other group will receive Cisplatin and Pemetrexed. The trial will measure how long participants live without their cancer getting worse, which is known as progression-free survival, as evaluated by an independent review center. The study will also consider factors like whether participants have brain metastasis and their overall health status to ensure fair comparisons. This study involves around 398 participants and aims to provide insights into which treatment might be more effective and safer for those affected.